Truist raises Ideaya Biosciences stock price target on trial data By Investing.com

Truist raised its price target on IDEAYA Biosciences to $65 from $60 while keeping a Buy rating after data showed darovasertib combination therapy achieved 6.9 months median progression-free survival and a 37% objective response rate in metastatic uveal melanoma. The firm now sees a higher probability of success and estimates peak revenue potential of more than $800 million in metastatic uveal melanoma and about $1.7 billion across all settings. Goldman Sachs also recently lifted its target to $35 from $31, reinforcing improving analyst sentiment around the oncology pipeline.

Analysis

IDYA is moving from “story stock” to a de-risked platform name: the new data meaningfully compresses the probability-weighted timeline to first approval, which is the key driver of multiple expansion in pre-revenue oncology. The market may still be underappreciating how a credible accelerated-approval path can re-rate the asset twice — first on the data readout, then again as regulatory milestones come into view over the next 12-18 months.

The second-order effect is on competitive positioning within uveal melanoma and adjacent oncology workflows. If the combination becomes the de facto backbone, late entrants will face a tougher adoption hurdle because oncologists tend to standardize around the first regimen that proves both tolerability and response durability; that can create a winner-take-most commercial dynamic even in a niche indication. The upside is not just label expansion, but leverage into future combo trials where each additional partner broadens addressable incidence without requiring a wholly new commercial infrastructure.

The main risk is that the current move may be front-running not just approval, but peak sales assumptions that depend on broad uptake and durable access. Any signal of weaker durability, safety concerns in real-world use, or payer pushback on a premium orphan-oncology launch could compress expectations quickly, and biotech multiples can reset sharply on even modest trial noise. GS’s neutral stance suggests the consensus still sees execution risk, so the stock could remain volatile until the regulatory package is actually filed and accepted.

From a trading standpoint, this is best expressed as a staged long rather than a chase: the data de-risks the bear case, but the valuation still depends on a multi-quarter bridge from clinical efficacy to commercial value. The asymmetric opportunity is to own the optionality while using defined-risk structures so the position survives any post-rally consolidation. AZN is a quieter beneficiary through collaboration optionality, but the direct earnings impact is too remote to drive shares meaningfully near term.

Key Decisions for Investors

• Initiate a 3-6 month long IDYA position on pullbacks rather than strength; reward/risk improves if the stock resets 10-15% after the first knee-jerk rally, with the next catalyst being regulatory filing/acceptance rather than more efficacy data.
• Buy IDYA call spreads 6-12 months out to capture approval-path optionality while capping downside; structure for a 2:1 or better payoff if the market starts pricing late-2026/early-2027 approval into 2025.
• For risk-managed exposure, pair long IDYA against a basket of cash-burning oncology peers with weaker late-stage data packages; the relative-value trade should work if capital rotates toward names with clearer regulatory trajectories.
• Avoid chasing GS on the headline because the move is more about target validation than fundamental earnings revision; the risk/reward is poor versus IDYA given the bank’s neutral posture and limited direct earnings sensitivity.
• Treat AZN as a watchlist item only; the collaboration adds pipeline breadth, but the near-term equity impact is low, so use it as a secondary beneficiary rather than a primary trade.